Internal Reference Number: FOI_8078
Date Request Received: 05/08/2024 00:00:00
Date Request Replied To: 21/08/2024 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Companies
| Question Number 1: How many patients were treated in the last 4 months (April to July 2024) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib | |
| Answer To Question 1: • Abrocitinib <5 • Acitretin 27 • Alitretinoin 5 • Azathioprine <5 • Baricitinib 0 • Ciclosporin 9 • Dupilumab 25 • Lebrikizumab 0 • Methotrexate 32 • Mycophenolate mofetil <5 • Pimecrolimus 10 • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only 11 • Tacrolimus ointment 34 • Tralokinumab <5 • Upadacitinib <5 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: • Age 6-11 5 • Age 12-17 8 • Age 18 and above 144 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
